Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Tuberous Sclerosis × Cannabidiol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Sturge-Weber Syndrome 2 Tuberous Sclerosis 1 Seizures 1 Glioblastoma 1 Drug Resistant Epilepsy 1 Cognitive Dysfunction 1 Chemotherapy-Induced Peripheral Neuropathy 1 Breast Neoplasms 1 Arthralgia 1 Anxiety Disorders 1

Interventions

Everolimus 8 Sirolimus 6 ganaxolone 3 carbon-11 acetate 1 Vigabatrin 1 Simvastatin 1 Melatonin 1 Cannabidiol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02544750 2022-07-14

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Jazz Pharmaceuticals

Phase 3 Completed

199 enrolled 14 charts

Seizures, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡